Zyprexa Relieves Nausea in Patients Treated for Head and Neck Cancer

Nausea and vomiting associated with anticancer therapies continue to be among patients’ most troubling symptoms. A recent clinical trial found that the medication Zyprexa (olanzapine) demonstrated comparative benefits in relieving these symptoms, especially for the relief of nausea overall and during the posttreatment phase two to five days after chemotherapy.

These results were presented during the 2015 annual meeting of the American Society of Clinical Oncology (ASCO), a gathering of nearly 30,000 oncology professionals in Chicago.

The randomized, double-blind, phase 3 trial compared Zyprexa with EMEND (fosaprepitant) in patients receiving concurrent highly emetogenic cisplatin-based chemotherapy (HEC) and local radiation therapy for advanced-stage head and neck and esophageal cancer.

One group enrolled 50 patients who received 10 mg of Zyprexa, along with .025 mg of palonosetron, and 20 mg of dexamethasone on day 1, followed by 10 mg of Zyprexa on days 2 to 4. In the second cohort, 49 patients received 150 mg of fosaprepitant plus .025 mg of palonosetron and 12 mg of dexamethasone on day 1 followed by 4 mg of dexamethasone on days 2 to 3.

The distribution of patients within the two groups was similar in gender, types of cancer and radiotherapy regimens.

Patients were evaluated during the acute period (24 hours postchemotherapy), the delayed period (two to five days postchemotherapy), and overall (0 to 120 hours postchemotherapy). The primary endpoint was complete response (CR). The secondary endpoint was a nausea score of zero on a scale of 0 to 10, with 10 equaling a high level of nausea and zero equaling no nausea.

CR was 88 percent in the Zyprexa group and 84 percent in the fosaprepitant group in the acute timeframe, and 76 percent in the Zyprexa group and 73 percent in the fosaprepitant group in both the delayed and complete timeframes.

For the secondary endpoint of nausea control, there was no significant difference between the Zyprexa group and the fosaprepitant group in the acute phase, with 86 percent of patients in the Zyprexa arm experiencing no nausea compared with 77 percent in the fosaprepitant arm.

However, there was a significant difference favoring Zyprexa in the delayed and overall phases, with 71 percent of patients in the Zyprexa arm experiencing no nausea compared with 41 percent in the fosaprepitant arm in both phases. This benefit was limited to nausea and did not include vomiting.

“In combination with palonosetron and dexamethasone, Zyprexa was comparable to fosaprepitant in the control of emesis in patients receiving concurrent highly emetogenic chemotherapy-radiation treatment,” says lead author on the study, Rudolph M. Navari, professor of medicine, associate dean and director, Indiana University School of Medicine.

The drugs were both well tolerated, and there were no grade 3 or 4 toxicities in either arm. CR and control of nausea in subsequent chemotherapy cycles were equal to or greater than cycle one for both regimens.

Zyprexa is currently approved by the FDA as an antipsychotic and is not approved for the control of nausea.

Previous studies have looked at Zyprexa as an antiemetic. In a phase 2 trial looking at the prevention of chemotherapy-induced nausea and vomiting in patients receiving their first course of either HEC or moderately emetogenic chemotherapy (MEC), Zyprexa was given with granisetron and dexamethasone prechemotherapy and with dexamethasone postchemotherapy.

In this study, nausea was found to be very well controlled in the patients receiving HEC, with no patient having nausea in the acute or delayed periods. Nausea was also well controlled in patients receiving MEC, with no nausea in 85 percent of patients in the acute period and in 65 percent of patients in the delayed and overall periods. There were no grade 3 or 4 toxicities.

The phase 3 study presented at ASCO confirms these findings, said Navari.

“Our results are consistent with current NCCN guidelines, recommending Zyprexa regimen as an option for chemotherapy-induced nausea vomiting prophylaxis for patients receiving HEC,” he says.

Navari R, Nagy C. Olanzapine versus fosaprepitant for the prevention of nausea and vomiting in patients receiving concurrent chemoradiation treatment. J Clin Oncol. 2015;33 (suppl; abstr 9502).